Ignite Creation Date:
2025-12-24 @ 2:51 PM
Ignite Modification Date:
2026-01-04 @ 8:43 AM
Study NCT ID:
NCT02843659
Status:
TERMINATED
Last Update Posted:
2018-10-04
First Post:
2016-07-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-10-18
Start Date Type:
ACTUAL
Primary Completion Date:
2017-07-24
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-07-24
Completion Date Type:
ACTUAL
First Submit Date:
2016-07-08
First Submit QC Date:
None
Study First Post Date:
2016-07-26
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-07-24
Results First Submit QC Date:
None
Results First Post Date:
2018-10-04
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-10-03
Last Update Post Date:
2018-10-04
Last Update Post Date Type:
ACTUAL